The strategic advice being handed around right now is to pivot to non-intoxicating products. It is the correct direction and it is usually delivered as though it were the easy option.
It is not the easy option. It is a harder formulation problem than what most of this industry has been doing, and it is worth being clear-eyed about why before committing a roadmap to it.
What the cap actually forces
Section 781 of Public Law 119-37 excludes finished hemp-derived cannabinoid products carrying more than 0.4 milligrams combined total per container of total THC including THCA, plus other cannabinoids with similar or similarly marketed effects. Effective 12 November 2026, 365 days after signing.
Note that the cap is combined and covers marketing intent. Swapping one intoxicating cannabinoid for another does not clear it. The route out is not a different cannabinoid, it is a different value proposition.
The uncomfortable part
An intoxicating product forgives a lot.
If the aromatic profile is roughly right, if the top notes have faded a little by month four, if batch three smells slightly different from batch one, most customers will not complain, because the thing they came for still works. The cannabinoid was covering for the formulation.
Take it out and every one of those becomes visible immediately. The profile is now the entire product. There is nothing else in the container doing work.
This is why “just make it non-intoxicating” understates the task. You are not removing an ingredient. You are removing the tolerance your formulation had for being approximately right.
Four things that get harder
Fidelity. An approximation of a cultivar profile reads as generic when nothing else is happening. The gap between a blend assembled from isolates to suggest a strain and a profile that genuinely reproduces one stops being a talking point and starts being the difference between a repeat purchase and a shrug.
Volatility. Monoterpenes are light and they leave. Sesquiterpenes are heavier and stay. A profile drifts as it ages, and it drifts unevenly, so it does not simply get weaker, it changes shape. If your product’s value is aromatic, storage and shelf stability is not a QA checkbox, it is product design.
Consistency. Batch-to-batch variation that nobody noticed before is now the customer complaint. Tightening it means tighter input specs, and tighter input specs mean a different conversation with suppliers than the one most brands have been having.
Dose and irritation. Terpenes are not inert, and “natural” is not a safety argument. Some are irritants above certain concentrations, and the tolerance differs sharply between a topical, a beverage and anything inhaled. Pushing concentration up to compensate for a missing cannabinoid is the obvious move and the wrong one. Terpene safety deserves deliberate attention here.
Format by format
Beverages. The hardest and the most promising. Terpenes are lipophilic, water is not cooperative, and the emulsion work behind solubility and flavor design is unforgiving. The prize is that the functional drinks category is already moving toward botanical positioning, so a well-built terpene-forward drink addresses a much larger market than a THC can ever did.
Topicals. The most natural fit, because this category never depended on intoxication. Oil-based systems are forgiving mediums for terpenes. The constraints are irritation thresholds and honest claims, which are the same constraints good topical formulation always had.
Inhalables. Technically straightforward and commercially exposed, because inhalation attracts regulatory attention independently. Boiling points matter more when the aromatic payload is the whole product.
What to do in the next four weeks
Find out which of your customers were buying the effect and which were buying the experience. Most brands assume they know and have never asked. The answer determines whether this is a pivot or an extinction event for a given SKU.
Then work the sourcing question, because fidelity and consistency are decided upstream. What your supply agreement actually commits your supplier to matters a great deal more when the profile is the product.
On the delay
The Senate text released 2 August 2026 would move most restrictions to 11 December 2026, and as of 5 August it had not passed either chamber. Four weeks is not a reformulation cycle. Treat it as noise and work to November.
About this article
Written 5 August 2026 and checked against the statute, the Federal Register and the published papers rather than against secondary coverage. Regulatory positions in this area are moving, so check the date before relying on it. Nothing here is legal, tax or medical advice.
